Polyclonal Antibodies Market Size
| Study Period | 2018-2029 |
| Market Size (2024) | USD 1.45 Billion |
| Market Size (2029) | USD 1.9 Billion |
| CAGR (2024 - 2029) | 5.53 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Polyclonal Antibodies Market Analysis
The Polyclonal Antibodies Market size is estimated at USD 1.45 billion in 2024, and is expected to reach USD 1.9 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).
COVID-19 significantly impacted the polyclonal antibodies market because it possessed a mutation that prevented antibody therapeutics from maintaining antiviral bindings and neutralizing efficacy. For instance, in March 2020, GigaGen, a US-based biotechnology company, developed a treatment called rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin). These polyclonal antibodies could be utilized to develop antibody therapeutics against future COVID-19 threats. According to the journal published by the National Library of Medicine in September 2023, during COVID-19, hundreds of antibodies were developed at preclinical and clinical stages in the format of polyclonal antibodies. Also, because of their potential to bind multiple targets and maintain their neutralizing activity despite mutations, these polyclonal antibodies have shown from animal origin to represent a promising approach. For instance, researchers developed XAV-19, a polyclonal antibody targeting COVID-19 that accelerated the recovery of mild to moderate COVID-19 patients. Thus, COVID-19 had a positive impact on the polyclonal antibodies market, and it was projected to witness lucrative growth in coming years owing to the development of new products and its pivotal role in treating noncurable diseases.
Further, infectious and chronic diseases can be considered as one of the biggest threats to humanity. There are many infectious diseases like Monkey Pox, Ebola, and Zika Virus and others. Antibodies and peptides are key to diagnosing and treating infectious diseases. According to a February 2022, Frontiers article, states that nontyphoidal Salmonella is a common cause of human bacterial enteritis. It causes approximately 93.8 million cases of gastroenteritis worldwide each year. Passive immunization with polyclonal hyperimmune globulin therapy is a proven strategy for delivering immunity. For instance, in May 2023, SAB Biotherapeutics, a biopharmaceutical company, announced the first publication of data for SAB-183 against Pneumonic Plague. It represented that the polyclonal antibodies derived from the transchromosomic bovine vaccinated with the recombinant vaccine increase bacterial opsonization in vitro and protect mice from the plague.
Moreover, chronic diseases like Cancer, Heart Disease, Stroke, Diabetes, Obesity, and many more are increasing globally. According to the article published by the World Health Organization in September 2023, 41 million people die from chronic diseases each year, which is equivalent to 74% of annual deaths. For instance, in the year May 2023, XENOTHERA, a clinical-stage biotechnology company, presented an abstract on its new product, XON7, which targets solid tumor cancer. It has shown promising effects on patients with the new line of treatments for several cancers.
Additionally, polyclonal antibodies are used in various diagnostic kits. It captures and detects antigens in patient samples in enzyme-linked immunosorbent assays. According to the article published by the National Library of Medicine in June 2022, these polyclonal antibodies are more accessible for developing and applying for fast and routine diagnostics in phytopathology and agricultural practice by Western immunoblotting assays. These polyclonal antibodies allow the binding of numerous antigenic determinants of the target, which results in better sensitivity in assays and leads to excellent stability. The biopharmaceutical industries have set up high standards for product efficacy, safety, and quality. For instance in April 2023, SAB Biotherapeutic recently announced positive results from phase 3 clinical trials of SAB-185 in patients with COVID-19 at high risk for severe complications.
However, limited availability of high-quality polyclonal antibodies as multiple cell clones generate polyclonal antibodies, and the resulting antibodies can vary in their affinity and specificity for the antigen. This factor can cause a hurdle in the growth of the polyclonal antibodies market.
Polyclonal Antibodies Market Trends
Secondary Antibody Segment is Expected to Dominate the Polyclonal Antibodies Market Over the Forecast Period
A secondary antibody recognizes an antibody or antibody domain from a different species. They bind primary antibodies in various experimental schemes and have immense applications in diagnostics therapeutics for infectious diseases caused by bacteria, viruses, protozoa and cancer, and metabolic and hormonal disorders. The segment is expected to hold a significant market share during the forecast period, owing to the rising investment in secondary antibody research and increased antibody-based product launches. For instance, in 2022, Jackson ImmunoResearch Laboratories launched their latest product, AffiniPure-VHH, and it will be used for high-resolution immunohistochemistry and immunofluorescence. Additionally, biopharmaceutical corporations are funding the development of novel antibody research that has the potential to benefit humanity by treating diseases. For instance, in March 2023, Pfizer, a leading biopharmaceutical industry, and Seagen, a biotechnology company, announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen. They will seek to accelerate the next generation of cancer by bringing power to antibody-drug conjugate and other innovative antibody platforms that directly engage the immune system to destroy tumors.
Furthermore, factors such as rising research and development leading to product approvals and launches are also fuelling the segment growth. For instance, In October 2023, a US-based biotechnology company, Proteintec, a global leader in antibodies, launched Multi-rAb Recombinant Secondary Antibodies, the newest generation of secondary antibodies designed to deliver unparalleled specificity and reproducibility in widely used immunoassays. Hence, these all have contributed to the significant growth of the market.
North America is Expected to Dominate the Polyclonal Antibodies Market over the Forecast Period
North America is expected to hold a significant share of antibody production owing to the high prevalence of cancer in the region, the strong presence of favorable healthcare infrastructure, and innovations and product launches by market players in the area.
The American Cancer Society Cancer Statistics 2022 states that there will likely be 1.92 million new cases of cancer diagnosed in the country. Leukemia is expected to have 60,650 new cases, lymphoma to have 89,010 new cases, and breast cancer to have 290,560 new cases out of all cancer cases in the United States. The rise in the approval of antibodies for the treatment of cancer and other diseases will contribute to the market growth in this region. For instance, in April 2023, a US-based Biotechnology named Rallybio announced clinical proof of concept results for RLYB211, a polyclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Moreover, the antibody production expansion by key regional players is also fuelling market growth. For instance, in October 2022, SAB Biotherapeutic, a US-based clinical-stage Biopharmaceutical company, announced that the company had entered an exclusive manufacturing services contract with Emergent BioSolutions Inc., a biopharmaceutical company based in Canada. Emergent will develop contracts and manufacture CDMO services to produce SAB’s fully human polyclonal antibody products.
Hence, factors such as increased demand for biological medicine, which drives antibody production, as well as the development of revolutionary technologies and product launches, will drive profitable growth in the region throughout the projection period.
Polyclonal Antibodies Industry Overview
The polyclonal antibodies market is consolidated due to a few companies operating globally and regionally. The competitive landscape includes analyzing a few international and local companies, including F. Hoffmann-La Roche AG, Emergent BioSolutions Inc, Creative Diagnostics, Bio-Rad Laboratories, and SAB Biotherapeutics. The key players are involved in various strategic alliances such as acquisitions, collaborations, and new product launches to withstand their position in the global market.
Polyclonal Antibodies Market Leaders
-
Creative Diagnostics.
-
F. Hoffmann-La Roche AG
-
Emergent BioSolutions Inc.
-
SAB Biotherapeutics
-
Bio- Rad Laboratories
*Disclaimer: Major Players sorted in no particular order
Polyclonal Antibodies Market News
- October 2023: Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay. These antibodies can specifically bind to small molecule labels and offer customers multiple choices with Anti-FAM polyclonal antibodies.
- February 2023: Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.
Polyclonal Antibodies Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Global Prevalence of Infectious and Chronic Diseases like Cancer.
- 4.2.2 Use of Polyclonal Antibodies in various Diagnostic Testing and Biopharmaceutical Industries.
-
4.3 Market Restraints
- 4.3.1 Limited Availability of High Quality Polyclonal Antibodies
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Product Type
- 5.1.1 Primary Antibody
- 5.1.2 Secondary Antibody
-
5.2 By Source
- 5.2.1 Rabbit
- 5.2.2 Mouse
- 5.2.3 Goat
- 5.2.4 Horse
- 5.2.5 Other Animals
-
5.3 By Application
- 5.3.1 Diagnostic
- 5.3.2 Clinical Research
-
5.4 By End User
- 5.4.1 Hospitals
- 5.4.2 Academic and Research Centers
- 5.4.3 Bio-Pharmacuetical Industries
- 5.4.4 Biotechnology Companies
- 5.4.5 Diagnostics Centers
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Creative Diagnostics.
- 6.1.2 Merck Millipore
- 6.1.3 Bio- Rad Laboratories
- 6.1.4 Agilent Technologies
- 6.1.5 GeneTex
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 Lonza Group
- 6.1.8 Gallus Immunotech
- 6.1.9 IGY Life Sciences
- 6.1.10 Emergent BioSolutions Inc.
- 6.1.11 PerkinElmer Inc.
- 6.1.12 SAB Biotherapeutics
- 6.1.13 Immunoprecise Antibodies Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPolyclonal Antibodies Industry Segmentation
As per the scope of the report, the polyclonal antibody market comprises a group of antibodies that represent the body's normal immunological response to an antigen. These are a collection of immunoglobulin molecules that react to a certain antigen and isolate different epitopes from that antigen. The polyclonal antibody market is segmented by product type (primary antibody and secondary antibody), source type( rabbit, mouse, goat, horse, and other animals), application (diagnostic and clinical research), end-user (hospitals, academics, biopharmaceutical industries, biotechnology industries, and diagnostic centers), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Product Type | Primary Antibody | |
| Secondary Antibody | ||
| By Source | Rabbit | |
| Mouse | ||
| Goat | ||
| Horse | ||
| Other Animals | ||
| By Application | Diagnostic | |
| Clinical Research | ||
| By End User | Hospitals | |
| Academic and Research Centers | ||
| Bio-Pharmacuetical Industries | ||
| Biotechnology Companies | ||
| Diagnostics Centers | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Polyclonal Antibodies Market Research FAQs
How big is the Polyclonal Antibodies Market?
The Polyclonal Antibodies Market size is expected to reach USD 1.45 billion in 2024 and grow at a CAGR of 5.53% to reach USD 1.9 billion by 2029.
What is the current Polyclonal Antibodies Market size?
In 2024, the Polyclonal Antibodies Market size is expected to reach USD 1.45 billion.
Who are the key players in Polyclonal Antibodies Market?
Creative Diagnostics., F. Hoffmann-La Roche AG, Emergent BioSolutions Inc., SAB Biotherapeutics and Bio- Rad Laboratories are the major companies operating in the Polyclonal Antibodies Market.
Which is the fastest growing region in Polyclonal Antibodies Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2029).
Which region has the biggest share in Polyclonal Antibodies Market?
In 2023, the North America accounts for the largest market share in Polyclonal Antibodies Market.
What years does this Polyclonal Antibodies Market cover, and what was the market size in 2023?
In 2023, the Polyclonal Antibodies Market size was estimated at USD 1.37 billion. The report covers the Polyclonal Antibodies Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Polyclonal Antibodies Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Polyclonal Antibodies Industry Report
Statistics for the 2024 Polyclonal Antibodies market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Polyclonal Antibodies analysis includes a market forecast outlook to for 2024 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
